HSV-2-encephalitis in a patient with multiple sclerosis treated with ocrelizumab

被引：13

作者：

Dudek, M. I. R. ^{[1
]}

Thies, K. ^{[1
]}

Kammenhuber, S. ^{[2
]}

Boesel, J. ^{[1
,3
]}

Roesche, Johannes ^{[1
,4
]}

机构：

[1] Klinikum Kassels, Klin Neurol, Kassel, Germany

[2] Zentralbereich Apotheke, Gesundheit Nordhessen, Kassel, Germany

[3] Univ Southampton, Kassel Sch Med, Southampton, Hants, England

[4] Univ Med Rostock, Klin & Poliklin Neurol, Rostock, Germany

来源：

JOURNAL OF NEUROLOGY | 2019年 / 266卷 / 09期

关键词：

TYPE-2; ENCEPHALITIS;

D O I：

10.1007/s00415-019-09391-0

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：2322 / 2323

页数：2

共 4 条

[1] Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010 [J].

Faissner, Simon ;

Gold, Ralf .

CNS DRUGS, 2018, 32 (03) :269-287

[2] Atypical herpes type 2 encephalitis associated with normal MRI imaging [J].

Harrison, NA ;

MacDonald, BK ;

Scott, G ;

Kapoor, R .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2003, 74 (07) :974-976

[3] Safety of monoclonal antibodies for the treatment of multiple sclerosis [J].

McGinley, Marisa P. ;

Moss, Brandon P. ;

Cohen, Jeffrey A. .

EXPERT OPINION ON DRUG SAFETY, 2017, 16 (01) :89-100

[4] Reversible progressive cognitive decline due to herpes simplex type 2 encephalitis with normal MR imaging [J].

Urban, P. P. ;

Joehnck, W. ;

Pohlmann, C. ;

Marrakchi, S. ;

Bruening, R. .

JOURNAL OF NEUROLOGY, 2008, 255 (12) :1975-1977

← 1 →